EPISODE · Oct 16, 2025 · 22 MIN
Managing Toxicities of CDK4/6 Inhibitors in Hormone Positive Breast Cancer - Dr. Stephanie Graff
from Oncology Brothers: Practice-Changing Cancer Discussions · host Oncology Brothers
In this episode of Oncology Brothers, we dived deep into the world of CDK4-6 inhibitors, focusing on their side effects and management in breast cancer treatment. Joined by an esteemed guest, Dr. Stephanie Graff, a medical breast oncologist from Brown University Health. We explored the side effects and management strategies for three commonly used CDK4/6 inhibitors: ribociclib, abemaciclib, and palbociclib.Key topics discussed include:• The evolving role of CDK4/6 inhibitors in early breast cancer and adjuvant settings.• Detailed management of side effects such as QT prolongation, liver function tests, and diarrhea.• The importance of shared decision-making with patients regarding treatment options.• Insights into the latest clinical trial data and its implications for practice.Whether you're a healthcare professional or someone interested in oncology, this episode provides valuable insights into optimizing patient care while managing the complexities of CDK4-6 inhibitors.Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/Don't forget to like, subscribe, and check out our other episodes for more discussions on oncology treatments and patient management strategies!#CDK4/6inhibitors #BreastCancer #Ribociclib #Abemaciclib #Palbociclib #OncologyBrothers #SideEffectManagement #HRpositiveBC
What this episode covers
In this episode of Oncology Brothers, we dived deep into the world of CDK4-6 inhibitors, focusing on their side effects and management in breast cancer treatment. Joined by an esteemed guest, Dr. Stephanie Graff, a medical breast oncologist from Brown University Health. We explored the side effects and management strategies for three commonly used CDK4/6 inhibitors: ribociclib, abemaciclib, and palbociclib.Key topics discussed include:• The evolving role of CDK4/6 inhibitors in early breast cancer and adjuvant settings.• Detailed management of side effects such as QT prolongation, liver function tests, and diarrhea.• The importance of shared decision-making with patients regarding treatment options.• Insights into the latest clinical trial data and its implications for practice.Whether you're a healthcare professional or someone interested in oncology, this episode provides valuable insights into optimizing patient care while managing the complexities of CDK4-6 inhibitors.Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/Don't forget to like, subscribe, and check out our other episodes for more discussions on oncology treatments and patient management strategies!#CDK4/6inhibitors #BreastCancer #Ribociclib #Abemaciclib #Palbociclib #OncologyBrothers #SideEffectManagement #HRpositiveBC
NOW PLAYING
Managing Toxicities of CDK4/6 Inhibitors in Hormone Positive Breast Cancer - Dr. Stephanie Graff
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.